Purple Biotech (PPBT) Other Non Operating Income (2019 - 2025)
Purple Biotech (PPBT) posted quarterly Other Non Operating Income of -$3.5 million for Q4 2023, down 526.7% year-over-year from $819540.5 in Q4 2022, and down 526.7% quarter-over-quarter from -$558000.0 in Q4 2022.
Purple Biotech (PPBT) Other Non Operating Income (2019 - 2025) Analysis & Trends
Purple Biotech (PPBT) has reported Other Non Operating Income for 5 consecutive years, with -$3.5 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Other Non Operating Income fell 526.7% year-over-year to -$3.5 million; the TTM figure through Dec 2023 stood at -$12.0 million (down 33.15% YoY), while the FY2023 annual figure was -$3.5 million, down 314.83% from the prior year.
- Other Non Operating Income eased to -$3.5 million in Q4 2023 per PPBT's latest filing, from -$558000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $13000.0 in Q4 2021 and bottomed at -$7.9 million in Q4 2020.
- Historically, Other Non Operating Income has averaged -$2.5 million across 5 years, with a median of -$558000.0 in 2022.
- Annual changes were most pronounced in 2021 — Other Non Operating Income soared 100.16% — and 2022, when it tumbled 4392.31%.
- Purple Biotech's Other Non Operating Income stood at -$517000.0 in 2019, then slumped by 1433.46% to -$7.9 million in 2020, then surged by 100.16% to $13000.0 in 2021, then sank by 4392.31% to -$558000.0 in 2022, then sank by 526.7% to -$3.5 million in 2023.
- Business Quant data shows PPBT's Other Non Operating Income at -$3.5 million in Q4 2023, -$558000.0 in Q4 2022, and $13000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Purple Biotech | 133.62 | 133.62 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -147,000.00 |
| Sep 30, 2024 | 1.68 Mn |
| Jun 30, 2024 | -1.04 Mn |
| Dec 31, 2023 | -3.50 Mn |
| Dec 31, 2022 | -558,000.00 |
| Dec 31, 2021 | 13,000.00 |
| Dec 31, 2020 | -7.93 Mn |
| Dec 31, 2019 | -517,000.00 |